A recent target trial emulation among veterans with type 2 diabetes found that adding GLP-1 receptor agonists to basal insulin therapy did not improve insulin discontinuation rates. Researchers compared the effects of adding GLP-1RAs against adding SGLT-2i or DPP-4i therapy, but saw no significant difference in outcomes.

A new health brief highlights how artificial intelligence could become a powerful tool in managing Type 2 diabetes. The piece, created by Cleveland Clinic and shared on Newswise, is only available in full through paid plans, but the premise hints at technology’s growing role in healthcare.

Serena Williams has confirmed she joined the growing ranks of individuals using GLP-1 medication for weight loss. The 43-year-old tennis icon discussed her decision following her struggle to drop pounds after childbirth.